Using ex vivo studies, we have shown that IMCs have pro-tumourigenic properties by promoting the growth and EMT of AT2 cells in culture (Fig3) and abrogation of IMCs by the CCR1 inhibitor provides clear evidence for the pro-tumourigenic/tumour-supportive functions of IMCs (Fig4). The gene discussed is CCR1; the disease is neoplasm.